EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study

Persistent Developmental Stuttering Clinical Trial

Official title:
An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension

Status Completed

Clinical Trial Summary

The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Persistent Developmental Stuttering
Stuttering

Clinical Trial Details

NCT number	NCT00216255
Study type	Interventional
Source	Endo Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	April 2005
Completion date	July 2011

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04173949` - Explorative Study for Treating Persistent Developmental Stuttering With Ramipril	Phase 3
	Completed	`NCT00239915` - Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)	Phase 2